Advertisement

Topics

Galera Therapeutics, Inc. Company Profile

11:34 EST 17th December 2018 | BioPortfolio

Galera Therapeutics, Inc. is a clinical-stage biotechnology company, headquartered in Malvern, PA, focused on the development of breakthrough drugs targeting oxygen metabolic pathways. The Company's lead compounds are highly selective small molecule dismutase mimetics that closely mimic the activity of the human superoxide dismutase enzymes. While the biology of the superoxide dismutase family suggests a broad range of potential applications, Galera is initially focusing its development on the prevention of radiation-induced toxicity, including mucositis, and the treatment of cancer. For more information, visit www.galeratx.com.


News Articles [687 Associated News Articles listed on BioPortfolio]

Galera Therapeutics doses first patient in Phase III trial of GC4419

Galera Therapeutics has dosed the first patient in a Phase III clinical trial of avasopasem manganese (GC4419). The trial will evaluate...Read More... The post Galera Therapeutics doses first patient...

Galera Therapeutics Nabs $150 Million to Drive Lead Therapeutic Into Phase III

Privately-held Galera Therapeutics, Inc. secured $150 million in a Series C funding round that will be used to drive its experimental head and neck cancer treatment GC4419 into Phase III trials, as we...

Galera Therapeutics Announces Dosing of First Patient in Pivotal Phase 3 ‘ROMAN’ Clinical Trial of Avasopasem Manganese (GC4419)

MALVERN, Penn. — October 15, 2018 — Galera Therapeutics, Inc., a clinical-stage biotechnology company focused on the development of drugs targeting oxygen metabolic pathways with the potential to ...

Galera Therapeutics closes $70.2mm Series C round

Galera Therapeutics Inc. (developing cancer treatments that target oxygen metabolic pathways) raised $70.2mm through its Series C round. New investor Clarus led (and takes a board seat) and was joined...

Galera pulls in $150M from funding round, royalty deal

A round of Series C funding raised $70 million for Galera Therapeutics, which intends to launch a late-stage trial of GC4419  -More- 

Clarus provides Galera with $80mm through royalty financing tied to musositis drug sales

Cancer drug developer Galera Therapeutics Inc. entered an $80mm royalty financing agreement with Clarus (which also participated in Galera's concurrent $70mm Series C round). Under the royalty financi...

Galera Raises $150m To Take Lead Drug From Phase III To NDA Submission

Galera garnered $70m in Series C venture capital and $80m through a royalty deal tied to GC4419 and a follow-up...    

Galera Therapeutics Nabs $150 Million to Drive Lead Therapeutic Into Phase III http://dlvr.it/Qkj934 pic.twitter.com/oKaYdta4l3

Galera Therapeutics Nabs $150 Million to Drive Lead Therapeutic Into Phase III http://dlvr.it/Qkj934  pic.twitter.com/oKaYdta4l3

PubMed Articles [458 Associated PubMed Articles listed on BioPortfolio]

RNA Therapeutics (Almost) Comes of Age: Targeting, Delivery and Endosomal Escape.

RNA-targeted therapeutics for lipid disorders.

To summarize recent developments in the field of RNA-directed therapeutics targeting lipid disorders that are not effectively managed.

A Review of Therapeutics in Clinical Development for Respiratory Syncytial Virus and Influenza in Children.

Respiratory syncytial virus (RSV) and influenza are important viral pathogens worldwide. Children, in particular, bear considerable burdens of morbidity and mortality associated with these viruses. Th...

Pharmacokinetic Analysis of Intraocular Penetration of Latanoprost Solutions with Different Preservatives in Human Eyes.

Eyes on New Product Development.

Clinical Trials [165 Associated Clinical Trials listed on BioPortfolio]

A Study Designed to Compare the Safety and Pharmacokinetics of Intravenously Administered Superoxide Dismutase Mimetic GC4711 and GC4419 in Healthy Volunteers

The study will be a double-blind, randomized, crossover, single-dose assessment of IV-administered GC4711 compared to GC4419 in healthy volunteers. Consenting subjects will undergo screen...

Impact of Ibis on Patients With Advanced COPD

The purpose of this research is to determine if Ibis™, a digital therapeutics solution developed by Senscio Systems, reduces the emergency room visits and hospitalizations of patients wi...

HDL Acute Lipid Optimization in Homozygous Familial Hypercholesterolemia

Assess the effect on coronary atheroma of serial infusions of autologous selectively delipidated HDL/preβ enriched plasma following use of HDL Therapeutics PDS-2™ System

Ontogenesis of the P-Glycoprotein in Human Lymphocytes Influence of HIV and Antiretroviral Therapeutics

The P-glycoprotein (P-gp) is a membranous transporter that modulates the intracellular concentrations of many drugs and plays thus a major role in the efficacy of the therapeutics that act...

A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas

The purpose of this first-in-human study of CX-072 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of CX-072 administered i...

Companies [1286 Associated Companies listed on BioPortfolio]

Galera Therapeutics, Inc.

Galera Therapeutics, Inc. is a clinical-stage biotechnology company, headquartered in Malvern, PA, focused on the development of breakthrough drugs targeting oxygen metabolic path...

Aeris Therapeutics

Aeris Therapeutics is an emerging medical therapeutics company specializing in the development and commercialization of novel treatments for patients with emphysema and other adva...

Altair Therapeutics, Inc.

Based in San Diego, Altair Therapeutics, Inc. is a privately-held biopharmaceutical company developing novel therapeutics to treat human respiratory diseases. Altair Therap...

Vaxiion Therapeutics, Inc.

Vaxiion is dedicated to the design and development of intelligent drug-delivery technologies with special emphasis on targeted oncology therapeutics. Vaxiion Therapeutics was spun...

Click Therapeutics, Inc.

Click Therapeutics, Inc. engineers, validates, and commercializes Digital Therapeutics™ solutions to benefit people with unmet medical needs through cognitive and neurobehavi...

More Information about "Galera Therapeutics, Inc." on BioPortfolio

We have published hundreds of Galera Therapeutics, Inc. news stories on BioPortfolio along with dozens of Galera Therapeutics, Inc. Clinical Trials and PubMed Articles about Galera Therapeutics, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Galera Therapeutics, Inc. Companies in our database. You can also find out about relevant Galera Therapeutics, Inc. Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks



Searches Linking to this Company Record